Journal of Pharmaceutical Investigation

The Korean Society of Pharmaceutical Sciences and Technology (한국약제학회)
권호 표지
DOI QR코드

DOI QR Code

Encapsulation of Plasmid DNA in Pegylated Liposome

  • Published : 2005.10.20
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of the study was to prepare the pegylated liposome carrying plasmid DNA with optimal encapsulation efficiency. Plasmid DNA (pCEP4 clone 790, 10.6 kb) was entrapped in the pegylated liposome composed of neutral lipid, POPC (l-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine), cationic lipid, DDAB (dimethyl dioctadecyl ammonium bromide) and anionic lipids, DSPE-PEG 2000 (distearoyl phosphatidyl ethanolamine polyethylene glycol 2000) and DSPE-PEG 2000-maleimide by freezing/thawing method. Free plasmid DNA was separated from the encapsulated one by Sepharose CL-4B column chromatography. The DNA amount encapsulated into the pegylated liposome was increased as cationic lipid concentration, initial amount of plasmid DNA and total lipid amount were increased.

Keywords

References

  1. K.A. Boris-Lawrie and H.M. Temin, Recent advances in retrovirus vector technology, Curr. Opin. Genet. Dev., 3, 102-109 (1993) https://doi.org/10.1016/S0959-437X(05)80349-1
  2. T.A. Smith, M.G. Mehaffey, D.R. Kayda, J.M. Saunders, S. Yei, R.C. Trapnell, A. McClelland and M. Kaleko, Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice, Nature Genet., 5, 397-402 (1993) https://doi.org/10.1038/ng1293-397
  3. Y. Setoguchi, H.A. Jaffe, C.-S. Chu and R.G. Crystal, Intraperitoneal in vivo gene therapy to deliver alpha 1-antitrypsin to the systemic circulation, Am. J. Resp. Cell Mol. Bioi., 10, 369-377 (1994) https://doi.org/10.1165/ajrcmb.10.4.8136153
  4. Y. Yang, F.A. Nunes, K. Berencsi, E.E. Furth, E. Gonczol and J.M. Wilson, Cellular immunity to viral antigens limits E1-deleted adenovirus for gene therapy, Proc. Natl. Acad. Sci. USA, 91, 4407-4411 (1995)
  5. Y. Yang, Q. Li, H.C.J. Erte and J.M. Wilson, Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses, J. Virol., 69, 2004-2015 (1995)
  6. A.D. Miller, Retrovirus vector, Curr. Top. Microbiol. Immunol., 158, 1-23 (1992)
  7. S. Worgall, G. Wolff, E. Falck-Pedersen and R.G. Crystal, Nonimmune mechanisms dominate elimination of adenovirus vectors following in vivo administration, Hum. Gene Ther., 8, 37-44 (1997) https://doi.org/10.1089/hum.1997.8.1-37
  8. B.T. Lamb, S.S. Sisodia, A.M. Lawler, H.H. Slunt, C.A. Kitt, W.G. Keams, P.L. Pearson, D.L. Price and J.D. Gearhart, Introduction and expression of the 400 kilobase precursor amyloid protein gene in transgenic mice, Nature Genet., 5, 22-30 (1993) https://doi.org/10.1038/ng0993-22
  9. S. Li and L. Huang, Nonviral gene therapy: promises and challenges, Gene Ther., 7, 31-34 (2000) https://doi.org/10.1038/sj.gt.3301110
  10. A.G. Schatzle in Non-viral vectors in cancer gene therapy: principles and progress, Anti-Cancer Drugs, 12, 275-304 (2001) https://doi.org/10.1097/00001813-200104000-00001
  11. G.S. Harrison, Y. Wang, J. Tomezak, C. Hogan, E.J. Shpall, T.J. Curiel and P.L. Felgner, Optimization of gene transfer using cationic lipids in cell lines and primary human CD4+ and CD34 hematopoietic cells, Biotechniques, 19, 816-823 (1995)
  12. C.M. Ward, M.L. Read and L.W. Seymour, Systemic circulation of poly(L-lysine)/DNA vectors is influenced by polycation molecular weight and type of DNA: differential circulation in mice and rats and the implications for human gene therapy, Blood, 97, 2221-2229 (2001) https://doi.org/10.1182/blood.V97.8.2221
  13. A. Kiehler, Gene transfer with modified polyethylenimines, J. Gene Med, 6, S3-S10 (2004) https://doi.org/10.1002/jgm.507
  14. E. Piskin, S. Dincer and M. Turk, Gene delivery: intelligent but just at the beginning, J. Biomater. Sci., 15, 1181-1202 (2004) https://doi.org/10.1163/1568562041753016
  15. D. Paphajopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.-D. Lee, M.C. Woodle, D.D. Lasic, C. Redemann and F.J. Marin, Sterically stabilized liposomes: improvement in pharmacokinetics and antitumor therapeutic efficacy, Proc. Natl. Acad Sci. USA, 88, 11460-11464(1991)
  16. N. Shi and W.M. Pardridge, Noninvasive gene targeting to the brain, Proc. Natl. Acad. Sci. USA, 97, 7567-7572 (2000)
  17. P.-A. Monnard, T. Oberholzer and P.L. Luisi, Entrapment of nucleic acids in liposomes, Biochim. Biophys. Acta, 1329, 39-50 (1997) https://doi.org/10.1016/S0005-2736(97)00066-7
  18. J. Huwyer, W. Dafang and W.M. Pardridge, Brain drug delivery of small molecules using immunoliposomes, Proc. Natl. Acad. Sci. USA, 93, 14164-14169 (1996)
  19. E.G. Sarabolac, O. Ludkovski, R. Skirrow, M. Ossanlou, Y.P. Zhang, C. Giebrecht, J. Thompson, S. Thomas, H. Stark, P.R. Cullis and P. Scherrer, Encapsulation of plasmid DNA in stabilized plasmid-lipid particles composed of different cationic lipid concentration for optimal transfection activity, J. Drug Target, 7, 423-437 (2000) https://doi.org/10.3109/10611860009102217
  20. K. Maruyama, O. Ishida, T. Takizawa and K. Moribe, Possibility of active targeting to tumor tissue with liposomes, Adv. Drug Deliv. Rev., 40, 89-102 (1999) https://doi.org/10.1016/S0169-409X(99)00042-3